Publication of 2023 financial results and operating update
Financial highlights include successful public rights offering and the subsequent 2024 buyback of all convertible bonds,…
Financial highlights include successful public rights offering and the subsequent 2024 buyback of all convertible bonds,…
4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage c…
Resminostat (Kinselby) as a maintenance therapy is now clinically proven to postpone disease progression in advanced Cut…
Die Medigene AG (Medigene oder das "Unternehmen", FWB: MDG1, Prime Standard) ein immunonkologisches Plattformunternehmen…
- Pentavere hat die branchenweit erste von Experten begutachtete (peer-reviewed) Arbeit veröffentlicht, in der KI und gr…
479,624 Warrants Z were exercised resulting in the issuance of 599,530 new ordinary shares Outstanding 3,326,104 War…
ProteinQure, the leading startup in the computational design of peptide drugs, announces a significant breakthrough in t…
Erste Wirksamkeitsdaten der klinischen Studie mit HDP-101 im Multiplen Myelom Erweiterung der ADC-Technologieplattform u…
Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objec…
The Board of Management of 4SC AG (4SC, FSE Prime Standard: VSC) announced today that according to its best judgment, th…